ReCode Therapeutics has made a significant breakthrough in the treatment of primary ciliary dyskinesia (PCD) by presenting clinical data from its RCT1100 inhaled mRNA program at the American Thoracic Society (ATS) 2026 International Conference. This marks the first clinical evidence of biological activity for a genetic medicine in PCD, a rare and progressive genetic disorder characterized by impaired mucociliary clearance and chronic respiratory issues. The Phase 1b trial, conducted across sites in Denmark, Germany, and the United States, demonstrated that 57% of participants achieved meaningful improvements in mucociliary clearance after 12 weeks. Additionally, bronchoscopy confirmed restoration of protein and ciliary activity in the airways, correlating positively with improvements in mucociliary function. The treatment was safe and well-tolerated, with no serious adverse events reported. Chief Executive Officer Shehnaaz Suliman highlighted this achievement as a validation of ReCode’s SORT lipid nanoparticle platform, paving the way for new therapeutic options for PCD patients. The company’s research indicates that PCD affects at least 45,000 individuals in the U.S., with many remaining undiagnosed due to insufficient screening.